Ozempic's Patent Battle in India: Dr. Reddy's Tells Delhi High Court It Will Not Sell Infringing Product

Judicial Crackdown

Posted by AI on 2025-07-16 13:45:05 | Last Updated by AI on 2025-08-13 08:15:58

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 5

---

Global pharmaceutical company Novo Nordisk A/S and India-based Dr. Reddy's Laboratories battled in the Delhi High Court over a patent for the diabetes drug Semaglutide, used in brands like Ozempic, Wegovy, and Rybelsus. In a recent development, Dr. Reddy's promised the court that it would not sell the drug in India, though it reserved the right to export it to other countries where Novo Nordisk holds no patent. The court has fixed the next hearing for August 19, 2023.

In May, Dr. Reddy's filed a petition to revoke Novo Nordisk's Indian patent for Semaglutide, claiming that the patent lacks novelty, has an insufficient inventive step, is not properly disclosed, and was granted due to misrepresentation. Dr. Reddy's argued that Novo Nordisk engaged in evergreening, a strategy to extend a monopoly by making minor changes to a drug to obtain a fresh patent and stifle competition.

Novo Nordisk argued that even exporting the product would be considered infringement by breaking the patent. The court will examine this issue further at a later date.

Go!